As of Wednesday close, Adaptive Biotechnologies Corporation’s (NASDAQ:ADPT) stock was down -$0.07, moving down -1.11 percent to $6.22. The average number of shares traded per day over the past five days has been 1,262,420 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.27 fall in that time frame. In the last twenty days, the average volume was 1,152,635, while in the previous 50 days, it was 1,124,946.
Since last month, ADPT stock retreated -18.05%. Shares of the company fell to $6.00 on 08/14/23, the lowest level in the past month. A 52-week high of $12.58 was reached on 01/18/23 after having rallying from a 52-week low of $5.96. Since the beginning of this year, ADPT’s stock price has dropped by -18.59% or -$1.42, and marked a new high 10 times. However, the stock has declined by -50.56% since its 52-week high.
ADPT stock investors should be aware that Adaptive Biotechnologies Corporation (ADPT) stock had its last reported insider trading activity 9 days ago on Aug 08. SOOD NITIN, the Chief Commercial Officer, MRD of the company, disposed of 10,550 shares for $6.54 on Aug 08. It resulted in a $68,997 divestment by the insider. SOOD NITIN sold 5,652 shares at an average price of $6.78 on Aug 07. The insider now owns 225,358 shares following the transaction. On Jun 20, Chief Financial Officer PETERSON TYCHO sold 134,961 shares at $8.14 apiece. The transaction was valued at $1,098,583.
Valuation Metrics
The stock’s beta is 1.23. Besides these, the trailing price-to-sales (P/S) ratio of 4.84, the price-to-book (PB) ratio of 2.27.
Financial Health
In the three months ended June 29, Adaptive Biotechnologies Corporation’s quick ratio stood at 4.80, while its current ratio was 5.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.32, and the total debt-to-equity ratio was 0.32. On the profitability front, the trailing twelve-month gross margin is 64.10% percent. Based on annual data, ADPT earned $127.4 million in gross profit and brought in $185.31 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -43.10%. Return on equity (ROE) for the past 12 months was -43.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ADPT’s revenue rose 10.77% to $37.65 million during the quarter, while net income inched up to $48.93 million. While analysts expected Adaptive Biotechnologies Corporation to report -$0.35 quarterly earnings, the actual figure was -$0.33 per share, beating the consensus estimate by 5.70%. During the quarter, the company generated -$44.08 million in EBITDA. The liabilities of Adaptive Biotechnologies Corporation were 368.57 million at the end of its most recent quarter ended June 29, and its total debt was $231.69 million. The value of shareholders’ equity is $144.65 million.
Technical Picture
This quick technical analysis looks at Adaptive Biotechnologies Corporation’s (ADPT) price momentum. With a historical volatility rate of 62.62%, the RSI 9-day stood at 26.42% on 16 August.
With respect to its five-day moving average, the current Adaptive Biotechnologies Corporation price is down by -4.16% percent or -$0.27. At present, ADPT shares trade -19.74% below its 20-day simple moving average and -20.66% percent below its 100-day simple moving average. However, the stock is currently trading approximately -17.07% below its SMA50 and -15.72% below its SMA200.
Stochastic coefficient K was 10.23% and Stochastic coefficient D was 8.86%, while ATR was 0.38. Given the Stochastic reading of 8.76% for the 14-day period, the RSI (14) reading has been calculated as 34.16%. As of today, the MACD Oscillator reading stands at -0.21, while the 14-day reading stands at -0.73.
Analyst Ratings
Adaptive Biotechnologies Corporation (ADPT) has been rated Overweight by analysts. According to 1 brokerage firm, ADPT is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Adaptive Biotechnologies Corporation stock as buy, with 7 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $7.00 – $15.00. Based on these forecasts, analysts predict Adaptive Biotechnologies Corporation (ADPT) will achieve an average price target of $11.88.
